Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3 - Wikidata - awgldk - TriplyDB

Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3

Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3

http://www.wikidata.org/entity/Q33718067

about

The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain Prodrugs of phosphonates and phosphates: crossing the membrane barrier Targeting SH2 domains in breast cancer Design, Synthesis, and Characterization of Small-Molecule Reagents That Cooperatively Provide Dual Readouts for Triaging and, When Necessary, Quantifying Point-of-Need Enzyme Assays A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library Progress towards the development of SH2 domain inhibitors.Long-Acting Beta Agonists Enhance Allergic Airway Disease Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form.Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity.Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Extolling the benefits of molecular therapeutic lipidation.Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept.Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6.Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b.Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells.Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance.Direct C-H difluoromethylenephosphonation of arenes and heteroarenes with bromodifluoromethyl phosphonate via visible-light photocatalysis.Geminal difunctionalization of α-diazo arylmethylphosphonates: synthesis of fluorinated phosphonates.Design and Synthesis of Fmoc-Thr[PO(OH)(OPOM)] for the Preparation of Peptide Prodrugs Containing Phosphothreonine in Fully Protected Form Palladium-catalyzed phosphonyldifluoromethylation of alkenes with bromodifluoromethylphosphonate Copper-catalyzed cross-coupling of bromozinc-difluoromethylphosphonate with iodo/bromo-aryl triazenes Palladium-Catalyzed Difluoroalkylation of Aryl Boronic Acids: A New Method for the Synthesis of Aryldifluoromethylated Phosphonates and Carboxylic Acid Derivatives

P2860

Q26861758-97DB215D-3E9C-428C-9F70-060B022B4E4C Q27005712-DBE9D9D5-A8D3-473C-83F6-7719551A8E13 Q27014674-AAD6774E-207B-47B2-AB1B-ABD3E7DE301C Q28394753-8B1D591C-2C76-4BEF-AA5F-9391C648CF88 Q33661939-A43A7F7D-27CF-4F3E-9753-53D377D5EFEF Q34026446-B734EA4D-E8C9-486A-9E21-A5E6CB3A0435 Q34581878-E3F93953-6F66-4597-9C2E-8074516B0755 Q35852118-DEF81DAD-C4D4-45D1-AA4C-706A75C1D0B0 Q35869426-6BD52463-1825-4BBA-AE25-994DC86FB3F2 Q36385313-71B58592-EE37-4ECC-9B06-DB08B1644B23 Q37239388-4B736F25-99F1-43E5-9A60-C8BDD48BC6B4 Q37414868-F1C7C5F9-25FA-41AE-8F5E-95F5CD5AB015 Q37683068-23C9D370-FF5C-4C09-B79E-7F8C049463BF Q37869903-49AC3C29-EA54-40A5-85EB-B2E1195ECA27 Q38114781-103F7720-3AD0-4706-A62F-D9EE9E949AAB Q38782370-619C3E9F-1229-4C49-88D2-D9B920B43886 Q39159381-70D9D9C1-2FBF-4811-81CB-E9A0F5037AF1 Q39514656-E8185EFB-B111-42D9-8A78-0C74CFB7BE81 Q39610489-9C0808AA-7C55-457F-B516-5A085376B86C Q39685915-49F51265-0540-4BDD-B051-60D3F03BEB2D Q39786751-ABAE86CB-97A3-47C8-9D0D-B0481AB81FCF Q42270755-E25D91E0-06B3-4962-9D7B-0517D1556947 Q47122836-9DE72B34-4FE7-4446-9C1C-04CAA1864147 Q47148273-78118661-ECA3-4B26-8956-0CDA3485F53F Q50220674-0367261B-0CCC-4531-8620-66FA91EF8F25 Q51132694-4340171F-D25F-4AFB-8D30-3B16A1343BEF Q58201491-3BBB2796-2A8A-48B1-9914-2A98F16423A7 Q58803301-12C55FDA-3D22-4A1D-ABD8-440E9D465072 Q58803310-EA2DA98C-DBFA-44CE-9841-36763CF1ED6B Q58803321-76601F59-44E7-4139-B512-A854EB8E1095

P2860

Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3

http://www.wikidata.org/entity/Q33718067

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@ast

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@en

type

label

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@ast

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@en

prefLabel

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@ast

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@en

P1433

Q33718067-D30D93A5-2E80-4FDE-8F0F-EA50661DCD36

P1476

Q33718067-24E48C37-18C7-4F5D-ACE3-69CEBCB3B074

P2093

Q33718067-232BF89F-2E42-4D86-9B37-0BF5FD39E07E

Q33718067-4D7E8D73-B817-47E9-AA29-5824528FAB01

Q33718067-F00D70C3-08AF-44B1-88E6-E1EA234CDA5E

P2860

Q33718067-02E3B87F-1E77-4999-88A2-476BC1B8AA88

Q33718067-14C8A830-2074-4C4C-BD9E-DF7E70E23FD4

Q33718067-19F988DC-99E0-4F61-823F-7A389511EE58

Q33718067-25950DF1-EC62-41C9-98AB-413F4DAA90DA

Q33718067-3CFBC0FF-0ABB-436B-9766-B1D0FA550857

Q33718067-798013E7-065B-4737-B911-A3FCFB057641

Q33718067-8D3BBB2A-B2F3-461F-97AB-61518D33DB98

Q33718067-94BA6040-1814-40FE-8471-5A8723214A21

Q33718067-9775BE19-E0FF-468F-B1ED-04A69BF3F025

Q33718067-B0FB0B3E-7517-4DF5-B2BC-B3381083A8E3

P304

Q33718067-1B962E2F-E01C-407F-BF47-9BED97E121E9

P31

Q33718067-188F49D2-DBAB-44B3-AD57-4AD67074E06B

P356

Q33718067-48BFF141-5E34-4A75-B768-5C2C835BFA86

P407

Q33718067-DE796F56-0020-4DB8-ADAD-BFA1958EEE9F

P433

Q33718067-D40F4056-9C7E-45DB-BE86-D12EF9F9B310

P478

Q33718067-5B52B96F-9FAA-4758-B7F6-2321676ADD42

P577

Q33718067-02FF5AF8-2560-4992-B6C6-8542C24D4CD5

P5875

Q33718067-48663454-FDFE-437E-93E4-E92DBFA009AB

P698

Q33718067-D25CA283-96D6-4E57-93CB-EE90EB6AD62E

P932

Q33718067-099150DA-6A92-4B78-BD99-DFDA4690F6A9

P356

P1433

Organic Letters

P1476

Synthesis of phosphatase-stabl ...... target the SH2 domain of Stat3

@en

P2093

John S McMurray

http://www.w3.org/2001/XMLSchema#string

Pijus K Mandal

http://www.w3.org/2001/XMLSchema#string

Warren S-L Liao

http://www.w3.org/2001/XMLSchema#string

P2860

The STATs of cancer--new molecular targets come of age

Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility.

Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.

Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.

Transcription factors as targets for cancer therapy.

Phosphotyrosyl mimetics in the development of signal transduction inhibitors.

Design and synthesis of phosphotyrosine peptidomimetic prodrugs

Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics.

Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties.

P304

3394-3397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/OL9012662

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26663006

http://www.w3.org/2001/XMLSchema#string

P698

19594124

http://www.w3.org/2001/XMLSchema#string

P932

2836187

http://www.w3.org/2001/XMLSchema#string